Interim data from phase III HAVEN 7 study reinforce Hemlibra's efficacy and safety in infants with severe haemophilia A without factor VIII inhibitors1New and updated data support use of Polivy in diffuse
Investegate announcements from F. Hoffmann-La Roche Ltd, Roche to present data at ASH 2022 showcasing strength of haematology portfolio and expanding into new areas to address more patient needs
First new treatment option in more than 20 years to show a clinically meaningful improvement in progression-free survival is approved for people with previously untreated diffuse large B-cell lymphoma
Investegate announcements from F. Hoffmann-La Roche Ltd, Roche’s Polivy combination approved by European Commission for people with previously untreated diffuse large B-cell lymphoma
Polivy plus R-CHP showed first clinically meaningful improvement in PFS with comparable safety in people with previously untreated diffuse large B-cell lymphoma (DLBCL) over the standard of care in more